David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
David Richards
Advertisement
CEO of Clarametyx Biosciences.
Articles by David Richards
Advertisement
Latest Updated Articles
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis PatientsPublished: October 24th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Top Infectious Disease News Stories Week of December 20 - December 26
2
From Awareness to Prevention: Addressing the Infection–Mental Illness–Violence Continuum
3
Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks
4
WHO Finds Progress in Malaria Prevention Measures
5